De-worming drug praziquantel could help reduce spread of HIV in Africa

NewsGuard 100/100 Score

Providing girls in rural Africa with a deworming drug could help reduce the spread of HIV, according to a study recently published in PLoS Neglected Tropical Diseases, the New York Times reports.

The drug, called praziquantel, costs about 32 cents per pediatric dose and prevents schistosomiasis, a worm disease that starts as a urinary tract infection. If untreated, schistosomiasis can lead to female genital sores that can facilitate HIV infection. Because the drug can kill the worms but cannot cure genital sores, girls should be protected before they reach sexual maturity, according to the Times.

"For this relatively small investment, the reproductive health of young women would be improved," the authors from the Sabin Vaccine Institute, Imperial College London and Oslo University wrote, adding that "there is a reasonable chance that HIV/AIDS transmission can be reduced." There are about 207 million schistosomiasis cases worldwide, 90% of which occur in Africa, where humans are exposed usually through snail-infested water. According to a pilot program conducted in Burkina Faso, all 70 million cases among young children in Africa could be treated for $22 million, and repeating universal treatment every two years for 10 years would cost $112 million (McNeil, New York Times, 5/26).

The study is available online.


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug candidates show promise to reverse HIV immune evasion